Disinta - Company finances
|
EUR
|
2021
From: 2021-03-18
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | - | 0 | - | 35,740 | 82,674 |
| Profit before tax | 0 | - | 0 | 3,639 | 2,777 |
| Net profit | 0 | 0 | 0 | 3,093 | 2,611 |
| Equity | 0 | 0 | 0 | 3,096 | 6,067 |
| Liabilities | - | 0 | 0 | 5,017 | 3,620 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 |
| Current assets | 0 | 0 | 0 | 8,113 | 9,687 |
| Total assets | 0 | 0 | 0 | 8,113 | 9,687 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | - | - | - | +131.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | - | - | - | 38.1% | 27.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | 99.9% | 43.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | - | 8.7% | 3.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | 10.2% | 3.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | 1.6 | 0.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Disinta - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-02-01 | 2024-02-29 | 6.24 |
Disinta - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Disinta, MB (company code 305717806) is a Small partnership operating in retail sale of pharmaceutical products. In 2025, the company generated revenue of €82.7K, up 131.3% year on year from €35.7K in 2024. Net profit for 2025 was €2.6K, compared with €3.1K in the prior year, while the profit margin narrowed to 3.2% from 8.7% in 2024. The two-year trend therefore shows strong sales expansion, but lower profitability relative to revenue growth.
The balance sheet remained small and conservative. At the end of 2025, total assets were €9.7K, equity €6.1K and liabilities €3.6K, giving an equity ratio of 62.6% and a debt-to-equity ratio of 0.60. Asset turnover was 8.53x, indicating high revenue generation relative to the asset base. Return on equity was 43.0% and return on assets 26.9% for 2025, reflecting positive earnings on a compact capital structure.
The balance sheet remained small and conservative. At the end of 2025, total assets were €9.7K, equity €6.1K and liabilities €3.6K, giving an equity ratio of 62.6% and a debt-to-equity ratio of 0.60. Asset turnover was 8.53x, indicating high revenue generation relative to the asset base. Return on equity was 43.0% and return on assets 26.9% for 2025, reflecting positive earnings on a compact capital structure.